Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 19Terminated 5Unknown 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 24Lymphoid 14Genitourinary 5Myeloid 2Plasma cell 1Gynecologic 1

Conditions

Prostatic Neoplasms 5Pain 1Neoplasms 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Mitoxantrone × Genitourinary × Clear all
NCT01522443 2018-05-23

COMET-2

Exelixis

Phase 3 Terminated
119 enrolled 21 charts
Genitourinary

Pain, Prostatic Neoplasms

NCT00477087 2017-11-29

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Stanford University

Phase 2 Terminated
10 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00447473 2016-03-17

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
31 enrolled
Genitourinary

Prostatic Neoplasms

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Centocor, Inc.

Phase 2 Terminated
106 enrolled 13 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00452387 2011-09-16

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Accelerated Community Oncology Research Network

Phase 2 Terminated
22 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡